Company Profile

Headquartered in Schertz, TX with research facilities in San Antonio, TX and additional offices in Europe, Evestra, Inc. is a biopharmaceutical R&D company having a therapeutic focus in women’s healthcare. Spun-off the Organic Chemistry Department of Texas Biomedical Research Institute (“TXBiomed”) the firm organizes around indications such as endometriosis, fibroids, fertility control (FC), hormone replacement therapy (HRT), and overactive bladder (OAB). Anchored in experience in hormonal steroidal drugs and with a product pipeline including pre-clinical products and clinical stage products, the firm's lead product candidate is EVE116, a second generation vaginal ring contraceptive that underwent Phase II clinical studies in Europe in early 2018 - first products to market involved collaborations with Gedeon Richter and Glenmark. Evestra’s competitive advantage is based on its founders’ and scientific advisors’ experience in pharmaceutical R&D in general, and of hin particular, combined with a proven track record in commercializing women’s healthca